In a previous study, we found a positive association between statin use and polyneuropathy risk. Other studies reported equivocal results. The present study aimed to confirm our findings with a design similar to that used in our previous study but with a larger data set.
Introduction
The use of cholesterol-lowering drugs, known as statins, has increased markedly in recent years. In Denmark, approximately 1% of the population used statins in 1999, and the proportion increased to more than 10% in 2014 [3] . Given the widespread use of statins, it is important to monitor patients to detect common and rare potential side effects. A number of studies on single cases and case series in the 1990s [4] [5] [6] [7] [8] [9] reported that statin use was a possible cause of polyneuropathy, a disease of the peripheral nerves. Polyneuropathy is estimated to affect approximately 2% of the general population, and its prevalence increases with age [10, 11] . Epidemiological studies on the putative association between statin use and polyneuropathy have provided equivocal results [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . We found in a previous study that statin use was positively associated with polyneuropathy risk [12] . However, some laboratory studies have reported that statins provided a neuroprotective effect against peripheral nerve injury [22] [23] [24] . Furthermore, it remains unclear whether hypercholesterolaemia per se has a deleterious effect on peripheral nerves [25] . In the present study, we reassessed the issue of whether statin use affects polyneuropathy risk in a large dataset with more statistical power than that of our original study. To improve the statistical power, we included data collected recently over a long study period. Furthermore, to facilitate comparisons between our present and past studies, and in recognition of several methodological strengths of our previous approach, we performed the current study with a design highly similar to that of our original study.
Methods
The present case-control study was based on data retrieved from the Odense University Hospital Registry (Patient Registry) and the Odense Pharmacoepidemiologic Prescription Database (Prescription Registry), which covered a geographically well-defined area in Denmark, Funen County (484 346 inhabitants in 2009) [26] . The civil registration number, unique to all Danish citizens, ensured correct linkage of information across registries. Codes were used to identify potential cases, drug exposure and comorbidity (Appendix 1).
Case ascertainment and validation
We retrieved information from the Patient Registry on all admissions and outpatient contacts in hospitals in Funen County, from January 1994 to December 2013. We identified patients with codes compatible with polyneuropathy of any type ( Figure 1 ). We then restricted the sample to patients with codes compatible with potentially idiopathic polyneuropathy (i.e. polyneuropathy of no known cause), recorded for the first time in the 1999-2013 period. The date of the first identified record of any of these codes was considered the index date.
We excluded patients based on criteria observed before or within the 6 months following the index date. We included the later time frame, owing to the possibility that a comorbidity (e.g. diabetes) might be diagnosed during the polyneuropathy work-up. The exclusion criteria were: (i) codes for polyneuropathy from a specific cause -e.g. diabetes or alcohol overuse; (ii) admission or outpatient data that included codes for diabetes, hypothyroidism, chronic kidney insufficiency, alcohol overuse or disorders related to alcohol overuse, human immunodeficiency virus, monoclonal gammopathy or cancer (except nonmelanoma skin cancer); and (iii) redeemed prescriptions for antidiabetic agents, thyroid substitution drugs or drugs for treating alcohol overuse (Prescription Registry). Furthermore, we included only patients aged 20-84 years who had resided in Funen County for at least 5 years prior to the index date. Cases identified in the last 3 months of 2013 were excluded, owing to a lack of data on residency status for that period (n = 14). Finally, we excluded patients who had been included in a previous study performed by our group (n = 1) [12] . Patients selected based on these criteria were included in the present study as potential cases.
For potential cases, medical records were traced and blinded with regard to information on drug use and personal identifiers. Subsequently, a neurology trainee (T.d.K.S) manually reviewed potential cases under the supervision of a neurologist with a special interest in neuromuscular disorders (S.H.S.). The criteria for accepting a diagnosis of idiopathic polyneuropathy were predefined (Appendix 2). We also collected the dates of symptom onset and diagnosis. In analyses restricted to validated cases, the index date was defined as the earliest of the following: date of symptom onset, date of diagnosis or date of first identified hospital entry of a polyneuropathy code.
Controls
For each potential case, we identified controls from the general population residing in the catchment area. Controls were identified in a local database, which included a demographic module with vital status and history of migration (i.e. dates of moves to and from the geographically well-defined catchment area) for all residents of the region [26] . Controls were selected when, on the index date, they matched a potential case in terms of age (year of birth) and gender. From these eligible controls, after applying the exclusion criteria mentioned above, we retained 20 controls per case. Some cases could be selected as controls prior to their diagnosis date (index date). Thus, the odds ratios (ORs) generated in the present study were unbiased estimates of the incidence rate ratios that would have emerged from a cohort study based on the same source population [27] .
Drug exposure
The Prescription Registry provided complete data on all reimbursed prescriptions filled at community pharmacies by residents of Funen County, Denmark, since November 1992 [26] . The data included the date of dispensation and a full product description, including the anatomical Figure 1 Flowchart of case ascertainment therapeutic code [28] , the number of dose units, the dosage form and the total number of defined daily doses (DDDs) contained in the dispensed package. The DDD was defined as the average maintenance dose per day assumed for a drug used for its main indication in adults (for statin DDD values, see Appendix 1) [28] . No information was available in the Prescription Registry on the indication for use or the dose prescribed by the physician.
We retrieved from the registry all available information on statin use for all subjects. We classified subjects by their use of statins prior to the index date as follows: ever users (≥1 statin prescriptions) or never users (no statin prescriptions). Subjects were further classified by how recently these drugs had been used, the duration of use and the intensity of use (see Supporting Information for details). We calculated the duration and intensity of statin use for the group with ever use (with the hypothesis that statins have a cumulative effect) and for the group with only current use (with the hypothesis that statins have a more immediate effect).
Analyses
We used conditional logistic regression to calculate the ORs and 95% confidence intervals (CIs) of statin exposure for cases with polyneuropathy compared with control subjects. The ORs were adjusted for the effects of several potential confounders, by design (i.e. matching patients and controls for age, gender and calendar period) and by restriction (i.e. exclusion of subjects with known polyneuropathy risk factors), as described above. Analyses were performed for the group with ever use and groups with current/past use; the group with never use was the reference group. During the study period, simvastatin was the dominant statin, accounting for 74% of total sales [3] . Analyses on other single drugs were performed when the numbers permitted.
Separate analyses were performed for the following types of cases and their corresponding controls:
1. Potential cases: data based purely on registry information.
Cases: cases verified through medical records (criteria in
Appendix 2), including:
a. All cases b. Definite cases c. Probable or possible cases.
We also performed some supplementary analyses. Based on all available registry data on potential cases and their corresponding controls, we classified subjects according to the type of lipid-lowering drug used, and we identified the most frequent patterns of lipid-lowering drug use. We excluded subjects exposed to various drugs reported to increase the risk of polyneuropathy (see Appendix 1), and we restricted the sample to cases defined according to narrow criteria (see Appendix 2), before performing the main analyses. Finally, because both quantitative sensory testing (QST) and skin biopsies had been implemented gradually in our department during the study period, we also analysed verified cases with either skin biopsy or QST results compatible with polyneuropathy, despite no indication of the diagnosis based on nerve conduction studies; this group of patients was not included in the main analyses ( Figure 1 ).
The study was approved by the Danish Data Protection Agency. According to Danish law, approval from an ethics board was not required for registry studies [30] .
Results
We identified 3104 patients in the catchment area with a first hospital contact code indicative of polyneuropathy in 1999-2013. Of these, 1146 were classified as potential cases. Statins were, by far, the most frequently used lipid-lowering drugs among these potential cases and their controls (Table S1 ). The diagnosis of idiopathic polyneuropathy could be validated in 370 cases, which were included in the main analyses. Another 56 patients with normal nerve conduction studies showed evidence of small fibre neuropathy on a QST or skin biopsy; these patients were only included in supplementary analyses. The most common reasons for study exclusion (n = 720) were a failure to confirm the diagnosis (n = 341) and an identification of non-idiopathic polyneuropathy (n = 308) ( Figure 1 ).
The characteristics of validated cases included in the main analyses are presented in Table 1 . Analyses based on Table 1 Characteristics of cases with idiopathic polyneuropathy Table 2) . We also performed a number of supplementary analyses. Analyses based exclusively on registry data (i.e. potential cases and their controls) showed slight to moderate associations between risk of polyneuropathy and some measures but the results were inconsistent (Table 3) . A restriction to cases that fulfilled the narrow Table 2 Use of statins and risk of idiopathic polyneuropathy definition of a neuropathy diagnosis had little impact on the estimates (Tables S2) . Additionally, risk estimates were similar when the analyses were restricted to subjects with no previous exposure to other drugs associated with an increased risk of polyneuropathy (Table S3) . Analyses of the subset of 56 cases with paraclinical test results compatible with small fibre neuropathy and their 1120 controls showed an OR of 1.65 (95% CI 0.65, 4.24) for subjects currently using statins and an increased risk of neuropathy (OR 4.20, 95% CI 1.28, 13.79) for subjects with past statin use (Table S4 ).
Discussion
We found no evidence of an association between statin use and the risk of idiopathic polyneuropathy in the present study. We expect this finding to be highly reassuring both for patients and care providers. Our findings are most strikingly at odds with the results of our own previous study, conducted in the same setting, where we found a strong association between statin use and idiopathic polyneuropathy (e.g. OR 4.6, 95% CI 2.1, 10-0, for patients who currently used statins) [12] . It is unlikely that design issues could explain the differences between our previous and current results because we used identical data sources and highly similar designs in the two studies. Furthermore, interobserver variation could only account for a minor part of the discrepancy in study results because in both studies we used similar predefined case definitions, assessed medical record information blinded for medication exposure, and provided supervision by the same expert in neuromuscular disorders (S.H.S.). However, the present study included information on more than twice as many cases as our previous study, and the subjects had much higher levels of statin exposure. Consequently, the present study had much higher precision than the former study, as reflected by the ratio between the upper and lower confidence limits of our main estimate (4.2 in the former study and 1.8 in the present study). Thus, although chance findings may be at play, the present study was less likely than the former study to have been affected by chance. Of note, we found no clear dose-response patterns that pointed to an association between statin use and the risk of idiopathic polyneuropathy. This negative finding further supported the lack of a causal association between exposure to statins and the development of idiopathic polyneuropathy. Our former study [12] was criticized for not being sufficiently rigorous because the subjects did not exclusively include strictly distal and symmetrical cases of polyneuropathy [30] . Despite that criticism, we chose to retain the same broad criteria in the present study to facilitate a straightforward comparison with our former study. Moreover, the ability to apply anatomical criteria was somewhat limited with our retrospective design because symptoms and findings were based on medical record information with variable completeness. We note that, in the present study, including only cases with distal symmetrical symptoms clearly stated in the medical records (see Appendix 2) had little impact on the results. The higher exposure frequency among controls compared with that in the previous study provided the present study with more power; however, it also implied that, in recent years, statins might have been prescribed for patients in a wider array of categories, compared with the subjects included in our original study. Thus, the strong signal we observed in our first Danish study may have indicated that statin use was a strong marker for risk factors of polyneuropathy -i.e. confounding factors associated with dyslipidaemia or other cardiovascular risk factors [25] . In recent times, statins have probably been prescribed more liberally [31] and may thereby be less strongly tied to particular patient characteristics. Indeed, in the present study, past statin use was more strongly associated with polyneuropathy risk than was current statin use. Moreover, an appreciation of the results of our former study may have led clinicians to discontinue statins at the first sign of polyneuropathy. The delays in referrals and diagnoses for this disorder could have led to the observed association between a first diagnosis of polyneuropathy and past statin use. Nevertheless, we consider this explanation unlikely because we received only a small number of referrals that specifically mentioned statin exposure as a possible cause of polyneuropathy (Gaist and Sindrup, personal communication). Likewise, although acute polyneuropathy has been reported in connection with statin use [32] , we believe that this potential side effect is extremely rare and unlikely to explain our findings concerning past statin use. Overall, we consider our current findings to be consistent with those of other studies that have found slight to moderate associations [14, 16] or no association [19, 20] between statin use and polyneuropathy. Consequently, we strongly urge that our results of a potential association between statin use and small fibre neuropathy, which were based on small numbers, should only be regarded as hypothesis generating. The present study had several strengths. First, we used population-based registries to screen for potential cases and to choose general population controls. Second, because the information on drug exposure in our study was based on registry data, we eliminated recall bias. Third, we only accepted cases where a polyneuropathy diagnosis was confirmed by the results of nerve conduction studies.
The study also had a number of potential limitations. In an effort to reduce confounding, we restricted cases to patients with no known risk factors for polyneuropathysuch as diabetes and high alcohol intake. Therefore, our results on the influence of statins on the development of polyneuropathy may not be generalizable to all patients with polyneuropathy. Furthermore, because the symptoms and signs of chronic polyneuropathy develop insidiously, a longer time frame than that employed in the present study might be necessary to capture an association between statin use and slowly evolving statin-induced polyneuropathy; these cases would not have been ascertained in the present study. In addition, we may have missed some patients with polyneuropathy, either because they were not suspected of having the disorder [33] or because they were referred to local private practice specialists. However, in the catchment area studied, nerve conduction studies are primarily conducted at our hospital; therefore, we assumed that the present study included the majority of recognized polyneuropathies in this area. More importantly, we did not suspect systematic biases related to where patients were examined for diagnosing polyneuropathy because all medical healthcare in Denmark is tax financed and free of charge, independent of income. However, we could not rule out the possibility that, in some instances, polyneuropathy might have been diagnosed without using neurophysiology tests; this possibility may particularly apply to mild cases of the disorder diagnosed in nonhospital settings. Nevertheless, this type of misclassification should not be related to whether a person was treated with or without statins.
Finally, because the present study was observational, we could not rule out the effects of poorly measured or unmeasured confounders.
In conclusion, the present study provided evidence that statin use is not associated with the risk of idiopathic polyneuropathy (i.e. polyneuropathy of no known cause).
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